Kaempferol suppresses prostate cancer metastasis and tumor angiogenesis via disrupting the LIMK1/Cofilin pathway
Biochemical and Biophysical Research Communications · 2026
DOI: 10.1016/j.bbrc.2025.153145 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2026. Verfasst von Peng Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Yantaishan Hospital, Yantai, Shandong, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Kaempferols, Neovascularization, Pathologic, Lim Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Tumor neovascularization promotes prostate cancer (PCa) progression, positioning anti-angiogenic therapy as a promising therapeutic strategy. Secondary metabolites from edible plants, particularly kaempferol, have demonstrated efficacy in suppressing PCa metastasis, yet its underlying mechanisms remain elusive. CCK-8 and colony formation assays were implemented to assess the cytotoxicity of kaempferol. Flow cytometry was executed to detect cell apoptosis and cell cycle arrest. The expression of molecules related to angiogenesis and cell cycle regulation was detected by immunofluorescence and Western blotting. A nude mouse prostate cancer xenograft model was established, with in vivo validation via H&E staining, ELISA, immunohistochemistry, and Western blotting assay. Kaempferol exerted pleiotropic anti-tumor effects on prostate cancer cells, including inhibiting the proliferation, inducing apoptosis and causing cell cycle arrest. Additionally, kaempferol decreased the expression of VEGFA, CDK4, and CDK6. Mechanistically, kaempferol disrupted the LIMK1/Cofilin signaling pathway, thereby inhibiting the angiogenic ability of tumor cells and suppressing the tumorigenic ability. In vivo xenograft experiments further confirmed kaempferol's efficacy in suppressing tumor growth. These findings support potential of kaempferol as a therapeutic agent for metastatic PCa. The identified LIMK1/Cofilin-dependent mechanism underscores the anti-metastasis effect of kaempferol and highlights LIMK1 as a therapeutic target, providing a rationale for further investigating kaempferol in prostate cancer progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Yantaishan Hospital, Yantai, Shandong, China.
- Department of Pharmacy, Yantaishan Hospital, Yantai, Shandong, China.
- Department of Urology, Yantai Yuhuangding Hospital, Yantai, Shandong, China. Electronic address: goodcoral123@163.com.
Zitieren
APA
Li, P., Lu, L., & Sun, Y. (2026). Kaempferol suppresses prostate cancer metastasis and tumor angiogenesis via disrupting the LIMK1/Cofilin pathway. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2025.153145
Vancouver
Li P, Lu L, Sun Y. Kaempferol suppresses prostate cancer metastasis and tumor angiogenesis via disrupting the LIMK1/Cofilin pathway. Biochemical and Biophysical Research Communications. 2026. doi:10.1016/j.bbrc.2025.153145
BibTeX
@article{Li2026,
author = {Li, Peng and Lu, Linqing and Sun, Yixiang},
title = {Kaempferol suppresses prostate cancer metastasis and tumor angiogenesis via disrupting the LIMK1/Cofilin pathway},
journal = {Biochemical and Biophysical Research Communications},
year = {2026},
doi = {10.1016/j.bbrc.2025.153145}
}
EUVIMED